Sign in
GERN Stock Price, Chart, Stats & News
Geron Corporation
Save
Geron Corporation (GERN) does not currently pay a dividend.
776.24M
Market cap
–
Current P/E
65.36x
Forward P/E
GERN chart
Fundamentals
Gross margin | 85.96% |
Operating margin | -29.28% |
Pretax margin | -46.65% |
Net margin | -46.65% |
Effective tax rate | – |
ROA | -15.04% |
ROE | -34.23% |
D/E | 1.11x |
Interest coverage ratio | -1.65x |
GERN valuation
P/E | – |
P/S | 4.88x |
P/B | 4.14x |
P/CF | -8.41x |
P/FCF | -8.07x |
P/OCF | -8.41x |
PEG | 1.31x |
EV multiple | -13.91x |
About
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies.
Similar securities
Based on sector and market capitalization
Report issue